Internal Medicine

With World Sickle Cell Day approaching, Dr. Titi Fasipe reflects on the developments within the field, such as the continued conversation of disparities and the increased comfort level with new therapies.

In the Archway trial, 93.2% of patients preferred treatment with ranibizumab delivered via the PDS compared to only 1.3% of patients who preferred intravitreal injections.

National prescribing cohort data suggest clinicians buck against the recommended use of the antidepressant.

Combination treatment was equal to anti-VEGF monotherapy in functional and structural outcomes in the treatment of macular edema due to BRVO.

An analysis of the SEARCH for Youth in Diabetes presented at ENDO 2022 details historic and contemporary disparities in insulin pump use for pediatric type 1 diabetes based on racial/ethnic background, household income, and insurance type.

Vutrisiran is the first and only FDA-approved treatment that’s demonstrated reversal in neuropathy impairment with subcutaneous administration once every 3 months.

On June 12, the Endocrine Society released new guidance for management of hyperglycemia in adult patients in noncritical care settings, which are cosponsored by the AACE, ADA, ADCES, and ESE.

New data suggest race and ethnicity, income, education, rural vs urban residence, and living in a food desert all were independently associated with poor diet quality.

The decision comes after the company announced positive phase 3 data for the combination vaccine candidate in adults aged 60 years and older.

The study popuation had a higher visual acuity at 12 months, despite receiving fewer aflibercept injections.

Some of the favorable responses to voxelotor treatment and signs of hematologic response after voxelotor treatment included increased Hb levels, decreased reticulocyte percentage, and decreased total bilirubin.

Hiddo Heerspink, PharmD, PhD, discusses a SURPASS-4 analysis examining kidney outcomes among patients receiving tirzepatide vs insulin glargine and provides perspective on the next steps for research as well as education.

New research from a review assessing risk of long COVID in patients with diabetes suggests the risk of developing long COVID in these patients could be more than 4-fold greater than the risk among patients without diabetes.

The phase 3 research being presented at the EULAR 2022 conference evaluated the efficacy and safety of upadacitinib in patients with active non-radiographic axial spondyloarthritis.

The investigators found pharmacotherapy for AUD was associated with a lower incidence of hepatic decompensation in patients with cirrhosis.

Efanescotocog alfa is the first factor VIII therapy to be granted Breakthrough Therapy designation by the FDA.

Bristol Myers Squibb shares positive phase 2 results evaluating deucravacitinib in patients with moderate-to-severe systemic lupus erythematosus.

Fidaxomicin had a 13.5% higher rate of 4-week sustained response compared to vancomycin and 13.2% higher rate for 8-week sustained response.

Patients with ≥1 CDI-related admissions versus no CDI admissions experienced higher rates of 6-month readmission and annual cost across all hospitalizations.

SER-109 engraftment was durable through week 24 and significantly higher than placebo at all time points for all comparisons.

New data suggests there is no connection between ustekinumab and the risk of malignancies.

There are several companies preparing new treatments for recurrent C difficile infections.

Data from a 1-year pragmatic trial examining use of a mobile health support system outlines the potential impact of using the system on weight loss and treatment effects among patients with pediatric obesity.

There are several potential treatments on the horizon for C difficile infections.

Primary care provider Dr. Gerald Smetana shares key information and resources to give PCPs all they need know about prescribing outpatient therapies for COVID-19.

The public perception of marijuana has shifted significantly, and Dr. Timothy Fong addresses how to keep up with progressive research and what risk factors still need to be better understood.

EoE expert Dr. Marc Rothenberg says it's a relief to know that the FDA has finally approved a drug for EoE.

NIDA research director Carlos Blanco-Jerez, MD, PhD, reviews how stigma, language barriers and digital health create disparate outcomes in mentally-ill Hispanic patients.

Lois Choi-Kain, MD, MEd, discusses her field's interest in improving the modern diagnosis and evidenced-based treatment of personality disorders.

The UCLA-based investigator discusses the unique impact of PTSD on patients' sleep stages, and how they can limit their insomnia.